论文部分内容阅读
美国FDA已批准SmithKlineBeecham公司的罗匹尼罗（ropinirol，商品名Requi）用于帕金森氏病征兆和症状的起始治疗，以及作为左旋多巴的辅助药物用于晚期帕金森氏病患者。在一项对轻至中度帕金森氏病患者的研究中，与安慰剂组相比，本品接受者在运动功能方面获得显著改善。且在?
The U.S. FDA has approved SmithKline Beecham’s ropinirol (Requi) for the initial treatment of signs and symptoms of Parkinson’s disease and its use as adjunctive levodopa in patients with advanced Parkinson’s disease. In a study of patients with mild-to-moderate Parkinson’s disease, the subject’s recipient achieved a significant improvement in motor function compared with placebo. And in?